BackSinovac Biotech, Overview

Sinovac Biotech, Other Current Liabilities

Latest other current liabilities for SVA: $1.2B.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.24B

Peer trimmed avg / median

Loading

Sinovac Biotech, Other Current Liabilities History

Loading

Sinovac Biotech, vs. peers: Other Current Liabilities Comparison

Loading

Sinovac Biotech, Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sinovac Biotech, (SVA) FAQ

As of the most recent data (December 2025), SVA shows a other current liabilities of $1.2B. Scroll down for historical charts and peer comparison views.

Tracking SVA's other current liabilities over time shows whether Sinovac Biotech, is scaling, shrinking, or reshaping that part of the business. The current reading is $1.2B Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Sinovac Biotech,'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.2B) with ownership activity and broader fundamentals.

Sinovac Biotech,'s other current liabilities is $1.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.